Why the study?
Cardiovascular comorbidities affect overall survival in patients with colorectal cancer, but a prognostic evaluation system accounting for these comorbidities is lacking.
Does a prognostic nomogram incorporating cardiovascular comorbidities accurately predict overall survival in patients with colorectal cancer?
Does a prognostic nomogram incorporating cardiovascular comorbidities accurately predict overall survival in patients with colorectal cancer?
Incorporating cardiovascular comorbidities such as heart failure and venous thromboembolism into a prognostic nomogram improves overall survival prediction for patients with colorectal cancer.
Answers are grounded in this paper and cite their sources.
May aid colorectal cancer risk stratification; hypothesis-generating and requires prospective validation before clinical use.
Background Cardiovascular comorbidities (CVCs) affect the overall survival (OS) of patients with colorectal cancer (CRC). However, a prognostic evaluation system for these patients is currently lacking. Objectives This study aimed to develop and validate a nomogram, which takes CVCs into account, for predicting the survival of patients with CRC. Methods In total, 21,432 patients with CRC were recruited from four centers in China between January 2011 and December 2017. The nomogram was constructed, based on Cox regression, using a training cohort (19,102 patients), and validated using a validation cohort (2,330 patients). The discrimination and calibration of the model were assessed by the concordance index and calibration curve. The clinical utility of the model was measured by decision curve analysis (DCA). Based on the nomogram, we divided patients into three groups: low, middle, and high risk. Results Independent risk factors selected into our nomogram for OS included age, metastasis, malignant ascites, heart failure, and venous thromboembolism, whereas dyslipidemia was found to be a protective factor. The c-index of our nomogram was 0.714 (95% CI : 0.708–0.720) in the training cohort and 0.742 (95% CI : 0.725–0.759) in the validation cohort. The calibration curve and DCA showed the reliability of the model. The cutoff values of the three groups were 68.19 and 145.44, which were also significant in the validation cohort ( p < 0.001). Conclusion Taking CVCs into account, an easy-to-use nomogram was provided to estimate OS for patients with CRC, improving the prognostic evaluation ability.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: